Therapeutic Advances in Oncology

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• The past five years saw 77 new oncology drug approvals by the FDA, yet significant unmet patient needs persist.
• Small molecules and antibodies are established therapeutic modalities, but novel approaches are crucial for advancing cancer care.
• Emerging therapies like antibody-drug conjugates, bispecific antibodies, peptides, cell, and gene therapies offer new hope.

Purpose of the Study:

• To provide a comprehensive overview of current and emerging therapeutic modalities in oncology.
• To discuss preclinical therapeutics for specific cancers, including breast cancer, lung cancer, and multiple myeloma.
• To highlight advancements in discovery and development platforms driving expanded treatment options.

Main Methods:

• Literature review of FDA-approved oncology drugs and emerging therapeutic technologies.
• Analysis of preclinical data for novel cancer treatments.
• Focus on therapeutic strategies for breast cancer, lung cancer, and multiple myeloma.

Main Results:

• While numerous oncology drugs have been approved, a substantial gap remains in effective treatments.
• Advancements in drug discovery, target identification, and technology are expanding the therapeutic landscape.
• Several promising preclinical therapeutics are under investigation for breast cancer, lung cancer, and multiple myeloma.

Conclusions:

• The field of oncology is rapidly evolving with diverse therapeutic modalities.
• Emerging therapies and preclinical candidates show potential to address unmet needs in major cancers.
• Continued innovation in development platforms is key to improving patient outcomes.